Video

Dr. Bhave on Promising Combination Strategies in TNBC

Manali Bhave, MD, discusses promising combination strategies in triple-negative breast cancer.

Manali Bhave, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, medical oncologist, Winship Cancer Institute, discusses promising combination strategies in triple-negative breast cancer (TNBC).

Scientific rationale suggests that adding targeted therapies to immunotherapy could enhance neoantigen expression and enhance the efficacy of immunotherapy in patients with TNBC, says Bhave.

Moreover, combinations of targeted therapy and immunotherapy may yield less toxicity vs chemotherapy and could, improve quality of life for this patient population, concludes Bhave.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD